BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tavakolpour S, Mirsafaei HS, Delshad S. Management of pemphigus disease in pregnancy. Am J Reprod Immunol 2017;77:e12601. [DOI: 10.1111/aji.12601] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Feliciani C, Genovese G, D'astolto R, Pontini P, Marzano AV. Autoimmune bullous diseases during pregnancy: insight into pathogenetic mechanisms and clinical features. G Ital Dermatol Venereol 2019;154:256-62. [PMID: 30375213 DOI: 10.23736/S0392-0488.18.06153-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Krammer S, Krammer C, Salzer S, Bağci IS, French LE, Hartmann D. Recurrence of Pemphigus Vulgaris Under Nivolumab Therapy. Front Med (Lausanne) 2019;6:262. [PMID: 31781569 DOI: 10.3389/fmed.2019.00262] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
3 Fenner J, Min MS, Liu S, Silverberg N. A case of neonatal pemphigus vulgaris with co-existing BP180 autoantibodies. Pediatr Dermatol 2020;37:241-3. [PMID: 31774569 DOI: 10.1111/pde.14059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Didona D, Maglie R, Eming R, Hertl M. Pemphigus: Current and Future Therapeutic Strategies. Front Immunol 2019;10:1418. [PMID: 31293582 DOI: 10.3389/fimmu.2019.01418] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 28.5] [Reference Citation Analysis]
5 Thomas RM, Colon A, Motaparthi K. Rituximab in autoimmune pemphigoid diseases: Indications, optimized regimens, and practice gaps. Clin Dermatol 2020;38:384-96. [PMID: 32563354 DOI: 10.1016/j.clindermatol.2019.07.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Popescu IA, Statescu L, Vata D, Porumb-Andrese E, Patrascu AI, Grajdeanu IA, Solovastru LG. Pemphigus vulgaris - approach and management. Exp Ther Med 2019;18:5056-60. [PMID: 31819769 DOI: 10.3892/etm.2019.7964] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Kridin K. Emerging treatment options for the management of pemphigus vulgaris. Ther Clin Risk Manag 2018;14:757-78. [PMID: 29740210 DOI: 10.2147/TCRM.S142471] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 9.3] [Reference Citation Analysis]
8 Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review. International Immunopharmacology 2018;54:131-8. [DOI: 10.1016/j.intimp.2017.11.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 14.0] [Reference Citation Analysis]
9 Tavakolpour S. Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus. Arch Dermatol Res 2018;310:95-106. [PMID: 29110080 DOI: 10.1007/s00403-017-1790-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
10 Genovese G, Derlino F, Berti E, Marzano AV. Treatment of Autoimmune Bullous Diseases During Pregnancy and Lactation: A Review Focusing on Pemphigus and Pemphigoid Gestationis. Front Pharmacol 2020;11:583354. [PMID: 33117178 DOI: 10.3389/fphar.2020.583354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]